About Anlon Healthcare Ltd IPO
Anlon Healthcare Ltd Mainboard IPO is going to hit the market on 26 August 2025 and closes on 29 August 2025. The price band for the issue has been fixed at ₹86 to ₹91 per share. The lot size for applying for the IPO is 164 shares. One can apply for 1 lot (164 shares) and multiples thereof. Anlon Healthcare IPO minimum application amount is ₹14,924 for the retailer. The company will raise a total of ₹121.03 crore through a 100% fresh issue of 1.33 crore equity shares, without any offer-for-sale. The allotment on September 1, 2025 and listing on NSE and BSE on September 3, 2025. Interactive Financial Services is the lead manager of the issue and KFin Technologies is the registrar to the issue.
Company Background
Anlon Healthcare Limited is a pharmaceutical manufacturer for the Indian formulators and export market and has its headquarters in Rajkot, Gujarat with the business being founded in 2013. The company's emphasis on process chemistry, documentation and adherence to global pharmacopeias, GMP-aligned systems in the product scaling and geography coverage scalability of the company. Conversion from a private to a public company in 2024 is also covered in the draft red herring prospectus, before its August 2025 listing timetable.
Operations & Product Range
Facility & Production
The organisation has multipurpose, GMP-compliant facilities around Rajkot, equipped to manage lab-to-plant scale-up and commercial production requirements, backed by utilities including solvent recovery and effluent treatment and QC instrumentation (HPLC/GC and wet labs) in line with statements made around API/intermediate production readiness. The process engineering team optimises the route, the impurity profile and the documentation so that technology transfers and validations can be conducted for both the client and various regulatory audits in India and certain export markets.
Brands & Market Presence
Being a B2B API/intermediates supplier, Anlon is not a consumer-facing name brand. Its “market presence” is primarily apparent in customer audits, DMF/documentation pathways and supply track records with domestic formulators and buyers in export markets, where purchasing teams assess quality systems and dossier completeness rather than retail brand identity.
Revenue Channels
- Supply of APIs & Intermediates to Indian Formulation Companies on a contractual basis/orders.
- Export sales into semi-regulated and regulated markets through documentation-backed SKUs.
- Custom synthesis /contract manufacturing for distinctive intermediates/APIs for B2B partners.
- Working capital-based scaling of volumes up with existing customers as new products are qualified.
Management & Shareholding
Promoters & Shareholding
The promoter group remains the majority owner pre-IPO(around 70.26%), which will be diluted proportionately with the fresh issue, yet they will drive strategic planning, capacity investment and regulatory filings, even as the company ramps up export-facing documentations and deliveries.
Board Members
The board is made up of executive directors from operations and strategy, as well as independent directors offering governance, finance and risk views. They serve to ensure that the company's internal controls and disclosures are consistent with the requirements of the mainboard listing.
IPO Objectives
- Capacity expansion and modernization of manufacturing facilities and utilities as outlined for scale-up.
- Working capital augmentation to support larger order books and export cycles.
- Debt reduction and general corporate purposes to strengthen the balance sheet and operations.
Conclusion
Anlon Healthcare IPO is positioned to fund scale-up in APIs and intermediates with a 100% fresh issue size of ₹121.03 crore under a price band of ₹86–₹91 and a minimum lot size of 164 shares to ensure the minimum ticket size remains in line with typical retail investors. The timeline through allotment September 1 and listing September 3 clearly establishes the path to trading, while the proceeds deployed towards capacity, working capital and balance-sheet strengthening enable the execution of a documentation-led, B2B driven growth plan in domestic and export markets.
Anlon Healthcare Ltd IPO Financial Information
Latest Revenue
77.37
₹ Crore
Profit After Tax
11.96
₹ Crore
Net Worth
71.86
₹ Crore
Total Borrowing
62.39
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 2025 | 160.96 | 77.37 | 11.96 | 71.86 | 62.39 | ||||
| 31 Mar 2024 | 128 | 67 | 10 | 21 | 74.56 | ||||
| 31 Mar 2023 | 111.55 | 113.12 | 5.82 | 7.37 | 66.39 | ||||
| 31 Mar 2022 | 84.97 | 57.54 | -0.11 | 1.55 | 60.32 | ||||
| Amount in ₹ Crore | |||||||||
Anlon Healthcare Ltd Key Performance Indicator
| KPI | Values |
|---|---|
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.21% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 6.38 | - |
| P/E (x) | 14.26 | - |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
End-to-end manufacturing capabilities from process development to the production of commercial API/intermediate under a GMP-driven system.
“Documentation emphasis and regulatory portfolio allow for customer audits and access to a variety of geographies.
Supplying through B2B relationships, domestic and export formulators that have repeat purchase attributes.
Process engineering and QA/QC rigor enabling scale-up, cost improvements and quality consistency.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |